Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Virotherapy Shows Promise Against Multiple Myeloma

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
A Mayo Clinic proof of principle clinical trial, demonstrated that virotherapy, destroying cancer with a virus that infects and kills cancer cells but spares normal tissues, can be effective against multiple myeloma.

Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.

“This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,” says Stephen Russell, M.D., Ph.D., Mayo Clinic hematologist, first author of the paper and co-developer of the therapy. “These patients were not responsive to other therapies and had experienced several recurrences of their disease.”

Multiple myeloma is a cancer of plasma cells in the bone marrow, which also causes skeletal or soft tissue tumors. This cancer usually responds to immune system-stimulating drugs, but eventually overcomes them and is rarely cured.

In their article, the researchers explain they were reporting on these two patients because they were the first two studied at the highest possible dose, had limited previous exposure to measles, and therefore fewer antibodies to the virus, and essentially had no remaining treatment options.

Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a history dating back to the 1950s. Thousands of cancer patients have been treated with oncolytic viruses from many different virus families (herpesviruses, poxviruses, common cold viruses, etc.). However, this study provides the first well-documented case of a patient with disseminated cancer having a complete remission at all disease sites after virus administration. 

The second patient in the paper, whose cancer did not respond as well to the virus treatment, was equally remarkable because her imaging studies provided a clear proof that the intravenously administered virus specifically targeted the sites of tumor growth. This was done using high-tech imaging studies, which were possible only because the virus had been engineered with a 'snitch gene' — an easily identifiable marker — so researchers could accurately determine its location in the body.

More of the MV-NIS therapy is being manufactured for a larger, phase 2 clinical trial. The researchers also want to test the effectiveness of the virotherapy in combination with radioactive therapy (iodine-131) in a future study.

The findings appear in the journal Mayo Clinic Proceedings

Other authors include Mark Federspiel, Ph.D., Kah-Whye Peng, Ph.D., M.Med., Caili Tong, David Dingli, M.D., Ph.D., William Morice, M.D., Ph.D., Val Lowe, M.D., Michael O’Connor, Ph.D., Robert Kyle, M.D., Nelson Leung, M.D., Francis Buadi, M.D., S. Vincent Rajkumar, M.D., Morie Gertz, M.D., Martha Lacy, M.D., and senior and corresponding author Angela Dispenzieri, M.D., all of Mayo Clinic.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Wednesday, August 26, 2015
Mayo, Baylor Collaborate
They aim to study genomic links to drug metabolism and other interactions which could be used to provide more tailored patient care.
Friday, May 15, 2015
First Steps in Formation of Pancreatic Cancer Identified
Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
Tuesday, November 11, 2014
Mayo Clinic Researchers Identify Role of Cul4 Molecule in Genome Instability and Cancer
Cul4 helps to deposit DNA-packaging histone proteins onto DNA, an integral step to help compact the genetic code.
Monday, November 11, 2013
Mayo Florida Receives $5M for Individualized Medicine Clinic
The donation from Florida residents Cecilia and Dan Carmichael will accelerate translation of research to patient care.
Wednesday, August 21, 2013
Mayo Clinic to Collaborate with Indian Science Leaders
The collaboration will cover areas such as drug, device and biomarker studies relating to heart disease, chemical biology, applied genomics and innovations in metabolomics.
Wednesday, October 19, 2011
TGen-Mayo Clinic Study Discovers Role of DNA Methylation in Multiple Myeloma
Report finds development of multiple myeloma is tied to ‘hypomethylation’.
Friday, October 01, 2010
Discovery Suggests Location of Genes for Breast Density, a Strong Risk Factor for Breast Cancer
Researchers at Mayo Clinic and H. Lee Moffitt Cancer Centers have identified a region on chromosome 5p that is associated with dense breast tissue.
Friday, September 07, 2007
Reactivating a Critical Gene Lost in Kidney Cancer Reduces Tumor Growth
Researchers have found that a key gene which is often silenced in clear cell renal cell carcinoma has stopped the tumor growth when restored in human kidney cancer cells.
Monday, August 20, 2007
Mayo Clinic Collaboration Discovers Protein Amplifies DNA Injury Signals
Protein MDC1 amplifies weak DNA injury signals so genetic repair can begin.
Friday, January 27, 2006
Researcher Discover Why Some DNA Repair Fails
This discovery may lead to ways of fixing the process to avoid Huntington's disease and some types of colon cancer.
Wednesday, October 05, 2005
Scientific News
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos